CAPLIPOINT - IntraDay Trade Analysis with Live Signals
Back to ListHere’s the intraday trading analysis for CAPLIPOINT based on the provided parameters
IntraDay Trade Rating: 4.1
| Stock Code | CAPLIPOINT | Market Cap | 17,947 Cr. | Current Price | 2,359 ₹ | High / Low | 2,447 ₹ |
| Stock P/E | 45.2 | Book Value | 270 ₹ | Dividend Yield | 0.25 % | ROCE | 27.0 % |
| ROE | 21.1 % | Face Value | 2.00 ₹ | DMA 50 | 2,007 ₹ | DMA 200 | 1,906 ₹ |
| Chg in FII Hold | -0.43 % | Chg in DII Hold | 0.09 % | PAT Qtr | 110 Cr. | PAT Prev Qtr | 87.3 Cr. |
| RSI | 73.1 | MACD | 128 | Volume | 59,039 | Avg Vol 1Wk | 1,29,866 |
| Low price | 1,500 ₹ | High price | 2,447 ₹ | PEG Ratio | 2.33 | Debt to equity | 0.00 |
| 52w Index | 90.7 % | Qtr Profit Var | 26.6 % | EPS | 52.2 ₹ | Industry PE | 32.1 |
📈 Optimal Buy Price: 2,340–2,360 ₹ (near current support)
💰 Profit-Taking Levels: 2,400–2,430 ₹ (short-term resistance)
🛑 Stop-Loss: 2,320 ₹ (below immediate support)
⏳ Exit Guidance: If already holding, consider exiting intraday if RSI falls below 65 or if price fails to sustain above 2,350 ₹ with declining volume. Current RSI at 73.1 and MACD at 128 show strong momentum, but volume (59,039) is well below the 1-week average (1,29,866), which may limit upside potential.
✅ Positive
- Quarterly PAT growth of 26.6% (110 Cr. vs 87.3 Cr.).
- EPS of 52.2 ₹ supports valuation strength.
- Strong ROCE of 27% and ROE of 21.1% indicate efficient capital use.
- Zero debt-to-equity ratio reduces financial risk.
- Stock trading above both 50 DMA (2,007 ₹) and 200 DMA (1,906 ₹), showing technical strength.
⚠️ Limitation
- High P/E of 45.2 compared to industry PE of 32.1 indicates premium valuation.
- PEG ratio of 2.33 suggests overvaluation relative to growth.
- Volume significantly below average, reducing intraday reliability.
📉 Company Negative News
- No major negative news reported recently, but FII holdings declined (-0.43%).
📊 Company Positive News
- Quarterly PAT improved (110 Cr. vs 87.3 Cr.).
- DII holdings increased (+0.09%), showing domestic institutional support.
🏦 Industry
- Pharmaceutical sector remains active with cyclical demand and export opportunities.
- Industry PE at 32.1 vs stock PE at 45.2 — stock trades at a premium.
🔎 Conclusion
⚖️ CAPLIPOINT is a strong candidate for intraday trading with momentum support. Buy near 2,340–2,360 ₹ and target 2,400–2,430 ₹ for profit-taking. Maintain strict stop-loss at 2,320 ₹ due to premium valuation and weaker volume. Intraday trades should be volume-confirmed, with exits aligned to RSI and MACD signals.
Would you like me to extend this into a peer benchmarking analysis against other pharma stocks like CIPLA, SUNPHARMA, and DIVISLAB to see relative intraday strength, or keep it strictly focused on CAPLIPOINT?